E143-Let’s talk about August sales numbers—and not so much about cannabis schedule III news

On this episode of the High Rise Cy and Emily decide not to talk too much about the recent news of the U.S. government’s potential move to reschedule cannabis to a schedule III controlled substance. At this point there’s no need to pontificate amongst all of the speculation bouncing around the industry until we get a substantial update from the government…so stay tuned everyone!  

Shifting gears, our hosts get into a thorough analysis of August's cannabis industry sales figures, putting a spotlight on some of the top brands making waves this month along with he following insights:

‍

• The overall market performance.
• The competitive landscape in Maryland's burgeoning cannabis market after its second month of sales – Who's coming out on top?
• A detailed breakdown of breakout brands, including the Elfbar clone in WA.
• The varying performances of MSOs in wholesale across different markets, with a case study contrasting &Shine's journey in Nevada vs. Illinois.
• An overview of top brands, basket trends, and a projection on how 2023 might wrap up for the industry.

‍
Stream through to the end of this data-backed episode to get a good 360-degree view of the current state and potential future of the cannabis industry.